Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Summary

Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

Timeline

Start

2021-07-14

Primary completion

2023-10-01

Completion

2023-10-01

Drugs

Indications